Myriad Genetics Inc (MYGN)

Apr 25, 2025, 4:05 PM EDT - 1 day ago

Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting

Apr 21, 2025, 4:05 PM EDT - 5 days ago

Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing

Apr 8, 2025, 4:15 PM EDT - 18 days ago

Myriad Genetics Announces Inducement Awards

Apr 7, 2025, 8:00 AM EDT - 19 days ago

Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer

Feb 25, 2025, 2:22 PM EST - 2 months ago

Myriad Genetics Faces Cost Restructuring As UnitedHealthcare Ends GeneSight Coverage, Appoints New CEO

UNH

Feb 24, 2025, 8:03 PM EST - 2 months ago

Myriad Genetics, Inc. (MYGN) Q4 2024 Earnings Call Transcript

Feb 24, 2025, 4:05 PM EST - 2 months ago

Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the second consecutive year of double-digit revenue growth

Feb 24, 2025, 8:30 AM EST - 2 months ago

Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio

Feb 19, 2025, 8:30 AM EST - 2 months ago

Myriad Genetics Included in Forbes America's Best Employers 2025 List

Feb 6, 2025, 8:30 AM EST - 2 months ago

Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test

Feb 5, 2025, 4:15 PM EST - 2 months ago

Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay

Feb 5, 2025, 8:30 AM EST - 2 months ago

Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration

Jan 29, 2025, 8:30 AM EST - 3 months ago

Myriad Genetics Unveils Groundbreaking Eight Weeks' Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference

Jan 23, 2025, 8:30 AM EST - 3 months ago

Myriad Genetics Introduces Online Prenatal Genetic Testing Resource

Jan 21, 2025, 8:30 AM EST - 3 months ago

Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology

Jan 15, 2025, 9:00 AM EST - 3 months ago

Diligent Announces Market Insights Reporting Powered by S&P Global Market Intelligence, Giving Directors and Executives Unrivaled Financial and Risk Insights

YEXT

Jan 9, 2025, 4:30 PM EST - 3 months ago

Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History

Jan 8, 2025, 11:27 AM EST - 3 months ago

UPDATE – Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Jan 8, 2025, 8:00 AM EST - 3 months ago

Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 8:00 AM EST - 3 months ago

Myriad Genetics Issues Quality, Innovation, and Corporate Responsibility Report

Dec 19, 2024, 4:15 PM EST - 4 months ago

Myriad Genetics' RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics

Dec 10, 2024, 6:26 PM EST - 4 months ago

Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing

Dec 10, 2024, 4:05 PM EST - 4 months ago

Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member

Dec 9, 2024, 4:05 PM EST - 4 months ago

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium

Nov 20, 2024, 4:30 PM EST - 5 months ago

Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina's Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2

Nov 18, 2024, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Shareholders to Learn More About the Investigation

Nov 17, 2024, 10:00 AM EST - 5 months ago

Myriad Genetics, Inc. (MYGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Nov 15, 2024, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Shareholders to Inquire about Securities Investigation

Nov 14, 2024, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Connect

Nov 13, 2024, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Investors to Connect

Nov 12, 2024, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Stockholders to Inquire about Securities Investigation

Nov 11, 2024, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Investors to Learn More About the Investigation

Nov 10, 2024, 10:00 AM EST - 5 months ago

Myriad Genetics, Inc. (MYGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Nov 9, 2024, 4:50 PM EST - 6 months ago

Myriad Genetics, Inc. (MYGN) Q3 2024 Earnings Call Transcript

Nov 8, 2024, 10:00 AM EST - 6 months ago

Myriad Genetics, Inc. (MYGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Nov 7, 2024, 4:05 PM EST - 6 months ago

Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance

Nov 7, 2024, 10:00 AM EST - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Stockholders to Learn More About the Investigation